TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Clinical Trial in Phase I-IIa to Study the Feasibility and Security of the Allogenic Use of Adipose-derived Stem Cells for the Local Treatment of Recto-vaginal Fistula in Crohn´s Disease
Brief Summary: The purpose of this study is to determine safety and efficacy of allogenic eASCs (expanded adult stem cells) for the treatment of recto-vaginal fistula in patients with Crohn´s disease.


Options:
A: Arm Label: Hematopoietic Stem Cell Transplant Regimen 2; Type: EXPERIMENTAL; Interventions: Biological: Hematopoietic stem cell transplantation | Intervention Type: BIOLOGICAL; Name: Hematopoietic stem cell transplantation; Assigned to Arm(s): Hematopoietic Stem Cell Transplant Regimen 2
B: Arm Label: Allogenic ASCs; Type: EXPERIMENTAL; Interventions: Drug: Expanded allogenic adipose-derived adult stem cells | Intervention Type: DRUG; Name: Expanded allogenic adipose-derived adult stem cells; Assigned to Arm(s): Allogenic ASCs
C: Arm Label: Treatment; Type: OTHER; Interventions: Procedure: Injection with freshly collected autologous adipose tissue | Intervention Type: PROCEDURE; Name: Injection with freshly collected autologous adipose tissue; Assigned to Arm(s): Treatment
D: Arm Label: ASCs; Type: EXPERIMENTAL; Interventions: Drug: ASCs (Cx401, company code) | Arm Label: ASCs+fibrin glue; Type: EXPERIMENTAL; Interventions: Drug: ASCs (Cx401, company code), Drug: Fibrin adhesive | Arm Label: Fibrin glue; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fibrin adhesive | Intervention Type: DRUG; Name: ASCs (Cx401, company code); Assigned to Arm(s): ASCs, ASCs+fibrin glue | Intervention Type: DRUG; Name: Fibrin adhesive; Assigned to Arm(s): ASCs+fibrin glue, Fibrin glue

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of HPN-100 for Maintaining Remission in Subjects With Cirrhosis and Episodic Hepatic Encephalopathy
Brief Summary: This is a phase 2 study of HPN-100 in subjects with hepatic encephalopathy (HE) consisting of an open label safety lead-in (Part A), followed by randomized, double-blind, placebo-controlled treatment (Part B).


Options:
A: Arm Label: HPN-100; Type: EXPERIMENTAL; Interventions: Drug: HPN-100 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: HPN-100; Assigned to Arm(s): HPN-100 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: GT4P-F; Type: EXPERIMENTAL; Interventions: Drug: HPN-100 | Arm Label: GT4P-API; Type: EXPERIMENTAL; Interventions: Drug: HPN-100 | Arm Label: Ammonul; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ammonul | Arm Label: Buphenyl; Type: ACTIVE_COMPARATOR; Interventions: Drug: Buphenyl | Intervention Type: DRUG; Name: HPN-100; Assigned to Arm(s): GT4P-API, GT4P-F | Intervention Type: DRUG; Name: Ammonul; Assigned to Arm(s): Ammonul | Intervention Type: DRUG; Name: Buphenyl; Assigned to Arm(s): Buphenyl
C: Arm Label: Polyethylene glycol 3350-electrolyte solution (GoLYTELY®); Type: ACTIVE_COMPARATOR; Interventions: Drug: Polyethylene glycol 3350-electrolyte solution (GoLYTELY®) | Arm Label: Lactulose; Type: OTHER; Interventions: Drug: Lactulose | Intervention Type: DRUG; Name: Polyethylene glycol 3350-electrolyte solution (GoLYTELY®); Assigned to Arm(s): Polyethylene glycol 3350-electrolyte solution (GoLYTELY®) | Intervention Type: DRUG; Name: Lactulose; Assigned to Arm(s): Lactulose
D: Intervention Type: DRUG; Name: HPN-100; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE RANGING STUDY EVALUATING THE EFFICACY AND SAFETY OF TANEZUMAB FOR THE TREATMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH INTERSTITIAL CYSTITIS/ PAINFUL BLADDER SYNDROME (IC/PBS).
Brief Summary: In a previous study in patients with interstitial cystitis/ painful bladder syndrome (IC/PBS), tanezumab has shown to be efficacious in relieving the pain associated with IC/PBS, as well as some effect on reducing urinary urgency. Only one dose was studied, and tanezumab was well tolerated. In this study, the hypothesis being tested is that tanezumab will show efficacy at several doses on reducing pain with sufficient tolerability. Tanezumab's safety will also be assessed at different dose levels


Options:
A: Arm Label: Group 1; Type: EXPERIMENTAL; Interventions: Biological: Tanezumab | Arm Label: Group 2; Type: EXPERIMENTAL; Interventions: Biological: Tanezumab | Arm Label: Group 3; Type: EXPERIMENTAL; Interventions: Biological: Tanezumab | Arm Label: Group 4; Type: EXPERIMENTAL; Interventions: Biological: Tanezumab | Arm Label: Group 5; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: BIOLOGICAL; Name: Tanezumab; Assigned to Arm(s): Group 1 | Intervention Type: BIOLOGICAL; Name: Tanezumab; Assigned to Arm(s): Group 2 | Intervention Type: BIOLOGICAL; Name: Tanezumab; Assigned to Arm(s): Group 3 | Intervention Type: BIOLOGICAL; Name: Tanezumab; Assigned to Arm(s): Group 4 | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Group 5
B: Arm Label: Global Therapeutic Massage (GTM); Type: PLACEBO_COMPARATOR; Interventions: Other: Global Therapeutic Massage (GTM) | Arm Label: Myofascial physical therapy (MPT); Type: ACTIVE_COMPARATOR; Interventions: Other: Myofascial physical therapy (MPT) | Intervention Type: OTHER; Name: Global Therapeutic Massage (GTM); Assigned to Arm(s): Global Therapeutic Massage (GTM) | Intervention Type: OTHER; Name: Myofascial physical therapy (MPT); Assigned to Arm(s): Myofascial physical therapy (MPT)
C: Arm Label: ASP6294; Type: EXPERIMENTAL; Interventions: Drug: ASP6294 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: ASP6294; Assigned to Arm(s): ASP6294 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Manual therapy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Manual therapy | Arm Label: Dry needling & manual therapy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Manual therapy, Procedure: Trigger point dry needling | Intervention Type: PROCEDURE; Name: Manual therapy; Assigned to Arm(s): Dry needling & manual therapy, Manual therapy | Intervention Type: PROCEDURE; Name: Trigger point dry needling; Assigned to Arm(s): Dry needling & manual therapy

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: High Dose of Erythropoietin Analogue After Cardiac Arrest: a Multicentre, Randomised, Controlled Trial (Epo-ACR-02 Trial)
Brief Summary: The investigators hypothesised that the neuroprotective effects of erythropoietin and its analogues could lead to an improve outcome after cardiac arrest. To test this hypotheses, the investigators designed a randomized, multicentre, simple blind trial in which all participating patients will be receive usual treatments and 50% of them will also receive a high dose of epoetin alpha (an analogue of erythropoietin) in an "add on" fashion. The main end point will be the proportion of patients in each arm who will reach at day 60 the best level of recovery, using a 5 level score.


Options:
A: Arm Label: EPO; Type: EXPERIMENTAL; Interventions: Drug: Darbepoetin alfa | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Darbepoetin alfa; Assigned to Arm(s): EPO | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Intervention Type: DRUG; Name: Erythropoietin; Assigned to Arm(s): N/A
C: Arm Label: Darbepoetin alfa; Type: EXPERIMENTAL; Interventions: Drug: Darbepoetin alfa | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Darbepoetin alfa; Assigned to Arm(s): Darbepoetin alfa | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: EPO; Type: EXPERIMENTAL; Interventions: Drug: EPOETINE ALPHA | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Other: Control arm | Intervention Type: DRUG; Name: EPOETINE ALPHA; Assigned to Arm(s): EPO | Intervention Type: OTHER; Name: Control arm; Assigned to Arm(s): Control

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Induction Chemotherapy Followed by Cetuximab Plus Definitive Radiotherapy Versus Radiation Plus Cisplatin
Brief Summary: A phase III trial of induction chemotherapy followed by definitive radiotherapy plus Cetuximab versus chemoradiation in unresectable, locally advanced, squamous cell carcinoma of the head and neck (HNC).


Options:
A: Arm Label: Induction chemotherapy + concurrent chemoradiotherapy; Type: EXPERIMENTAL; Interventions: Procedure: Induction chemotherapy + concurrent radiochemotherapy vs. concurrent radiochemotherapy | Arm Label: Concurrent radiochemotherapy alone; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Induction chemotherapy + concurrent radiochemotherapy vs. concurrent radiochemotherapy | Intervention Type: PROCEDURE; Name: Induction chemotherapy + concurrent radiochemotherapy vs. concurrent radiochemotherapy; Assigned to Arm(s): Concurrent radiochemotherapy alone, Induction chemotherapy + concurrent chemoradiotherapy
B: Arm Label: Arm I; Type: PLACEBO_COMPARATOR; Interventions: Procedure: conventional surgery, Radiation: radiation therapy | Arm Label: Arm II; Type: ACTIVE_COMPARATOR; Interventions: Biological: cetuximab, Procedure: conventional surgery, Radiation: radiation therapy | Intervention Type: BIOLOGICAL; Name: cetuximab; Assigned to Arm(s): Arm II | Intervention Type: PROCEDURE; Name: conventional surgery; Assigned to Arm(s): Arm I, Arm II | Intervention Type: RADIATION; Name: radiation therapy; Assigned to Arm(s): Arm I, Arm II
C: Arm Label: Arm A Patient FIT; Type: ACTIVE_COMPARATOR; Interventions: Drug: Cisplatin, Radiation: IMRT | Arm Label: Arm B Patient FIT; Type: EXPERIMENTAL; Interventions: Drug: Cetuximab, Drug: avelumab, Radiation: IMRT | Arm Label: Arm C Patient UNFIT; Type: EXPERIMENTAL; Interventions: Drug: Cetuximab, Drug: avelumab, Radiation: IMRT | Arm Label: Arm D Patient UNFIT; Type: ACTIVE_COMPARATOR; Interventions: Drug: Cetuximab, Radiation: IMRT | Intervention Type: DRUG; Name: Cetuximab; Assigned to Arm(s): Arm B Patient FIT, Arm C Patient UNFIT, Arm D Patient UNFIT | Intervention Type: DRUG; Name: avelumab; Assigned to Arm(s): Arm B Patient FIT, Arm C Patient UNFIT | Intervention Type: DRUG; Name: Cisplatin; Assigned to Arm(s): Arm A Patient FIT | Intervention Type: RADIATION; Name: IMRT; Assigned to Arm(s): Arm A Patient FIT, Arm B Patient FIT, Arm C Patient UNFIT, Arm D Patient UNFIT
D: Arm Label: ARM A; Type: EXPERIMENTAL; Interventions: Drug: docetaxel - cisplatin - 5-fluorouracil, Radiation: radiotherapy, Drug: cetuximab | Arm Label: ARM B; Type: ACTIVE_COMPARATOR; Interventions: Drug: cisplatin, Radiation: radiotherapy | Intervention Type: DRUG; Name: docetaxel - cisplatin - 5-fluorouracil; Assigned to Arm(s): ARM A | Intervention Type: RADIATION; Name: radiotherapy; Assigned to Arm(s): ARM A | Intervention Type: DRUG; Name: cetuximab; Assigned to Arm(s): ARM A | Intervention Type: DRUG; Name: cisplatin; Assigned to Arm(s): ARM B | Intervention Type: RADIATION; Name: radiotherapy; Assigned to Arm(s): ARM B

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Optimizing Social and Communication Outcomes for Toddlers With Autism
Brief Summary: This project will examine the efficacy of two different treatment approaches aimed at facilitating change in social and communications outcomes of toddlers with autism.


Options:
A: Intervention Type: BEHAVIORAL; Name: Joint attention intervention; Assigned to Arm(s): N/A
B: Arm Label: Caregiver Education Intervention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Caregiver-Education Intervention | Arm Label: Caregiver-Mediated Intervention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Caregiver-Mediated Intervention | Intervention Type: BEHAVIORAL; Name: Caregiver-Mediated Intervention; Assigned to Arm(s): Caregiver-Mediated Intervention | Intervention Type: BEHAVIORAL; Name: Caregiver-Education Intervention; Assigned to Arm(s): Caregiver Education Intervention
C: Arm Label: ESI--Individual PII First Condition; Type: EXPERIMENTAL; Interventions: Behavioral: Early Social Interaction Project- PII, Behavioral: Early Social Interaction Project- IES | Arm Label: ESI--Group IES First Condition; Type: EXPERIMENTAL; Interventions: Behavioral: Early Social Interaction Project- PII, Behavioral: Early Social Interaction Project- IES | Intervention Type: BEHAVIORAL; Name: Early Social Interaction Project- PII; Assigned to Arm(s): ESI--Group IES First Condition, ESI--Individual PII First Condition | Intervention Type: BEHAVIORAL; Name: Early Social Interaction Project- IES; Assigned to Arm(s): ESI--Group IES First Condition, ESI--Individual PII First Condition
D: Arm Label: JAE-EMT; Type: EXPERIMENTAL; Interventions: Behavioral: JAE Intervention | Arm Label: JAE-AAC; Type: EXPERIMENTAL; Interventions: Behavioral: JAE Intervention | Intervention Type: BEHAVIORAL; Name: JAE Intervention; Assigned to Arm(s): JAE-AAC, JAE-EMT

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Multicenter, Randomized, Blinded, Placebo-controlled, Crossover, Single-dose Study to Assess the Effect of Indacaterol (150 μg) Versus Tiotropium (18 μg) on Inspiratory Capacity in Moderate Chronic Obstructive Pulmonary Disease (COPD) Patients
Brief Summary: This study compared the effects of a single dose of indacaterol with that of a single dose of tiotropium on inspiratory capacity.


Options:
A: Arm Label: Fluticasone Furoate/Vilanterol; Type: EXPERIMENTAL; Interventions: Drug: Fluticasone Furoate 100mcg/Vilanterol 25mcg | Arm Label: Fluticasone Propionate/Salmeterol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fluticaosne Propionate 500mcg/Salmeterol 50mcg | Intervention Type: DRUG; Name: Fluticasone Furoate 100mcg/Vilanterol 25mcg; Assigned to Arm(s): Fluticasone Furoate/Vilanterol | Intervention Type: DRUG; Name: Fluticaosne Propionate 500mcg/Salmeterol 50mcg; Assigned to Arm(s): Fluticasone Propionate/Salmeterol
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Aclidinium bromide | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Aclidinium bromide | Intervention Type: DRUG; Name: Aclidinium bromide; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Aclidinium bromide; Assigned to Arm(s): 2
C: Arm Label: Indacaterol 150 μg-tiotropium 18 μg-placebo; Type: EXPERIMENTAL; Interventions: Drug: Indacaterol 150 μg, Drug: Tiotropium 18 μg, Drug: Placebo | Arm Label: Tiotropium 18 μg-placebo-indacaterol 150 μg; Type: EXPERIMENTAL; Interventions: Drug: Indacaterol 150 μg, Drug: Tiotropium 18 μg, Drug: Placebo | Arm Label: Placebo-indacaterol 150 μg-tiotropium 18 μg; Type: EXPERIMENTAL; Interventions: Drug: Indacaterol 150 μg, Drug: Tiotropium 18 μg, Drug: Placebo | Intervention Type: DRUG; Name: Indacaterol 150 μg; Assigned to Arm(s): Indacaterol 150 μg-tiotropium 18 μg-placebo, Placebo-indacaterol 150 μg-tiotropium 18 μg, Tiotropium 18 μg-placebo-indacaterol 150 μg | Intervention Type: DRUG; Name: Tiotropium 18 μg; Assigned to Arm(s): Indacaterol 150 μg-tiotropium 18 μg-placebo, Placebo-indacaterol 150 μg-tiotropium 18 μg, Tiotropium 18 μg-placebo-indacaterol 150 μg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Indacaterol 150 μg-tiotropium 18 μg-placebo, Placebo-indacaterol 150 μg-tiotropium 18 μg, Tiotropium 18 μg-placebo-indacaterol 150 μg
D: Arm Label: GSK573719/GW642444; Type: EXPERIMENTAL; Interventions: Drug: 62.5/25mcg | Arm Label: GSK573719; Type: EXPERIMENTAL; Interventions: Drug: 62.5mcg | Arm Label: GW642444; Type: EXPERIMENTAL; Interventions: Drug: 25mcg | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: 62.5/25mcg; Assigned to Arm(s): GSK573719/GW642444 | Intervention Type: DRUG; Name: 62.5mcg; Assigned to Arm(s): GSK573719 | Intervention Type: DRUG; Name: 25mcg; Assigned to Arm(s): GW642444 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Multicenter, Randomized, Blinded, Placebo-controlled, Crossover, Single-dose Study to Assess the Effect of Indacaterol (150 μg) Versus Tiotropium (18 μg) on Inspiratory Capacity in Moderate Chronic Obstructive Pulmonary Disease (COPD) Patients
Brief Summary: This study compared the effects of a single dose of indacaterol with that of a single dose of tiotropium on inspiratory capacity.


Options:
A: Arm Label: Indacaterol 150 μg; Type: EXPERIMENTAL; Interventions: Drug: Indacaterol 150 μg, Drug: Placebo to Salmeterol | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo to Indacaterol, Drug: Placebo to Salmeterol | Arm Label: Salmeterol 50 μg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Salmeterol 50 μg, Drug: Placebo to Indacaterol | Intervention Type: DRUG; Name: Indacaterol 150 μg; Assigned to Arm(s): Indacaterol 150 μg | Intervention Type: DRUG; Name: Salmeterol 50 μg; Assigned to Arm(s): Salmeterol 50 μg | Intervention Type: DRUG; Name: Placebo to Indacaterol; Assigned to Arm(s): Placebo, Salmeterol 50 μg | Intervention Type: DRUG; Name: Placebo to Salmeterol; Assigned to Arm(s): Indacaterol 150 μg, Placebo
B: Intervention Type: DRUG; Name: Salmeterol 50mcg/ Fluticasone Propionate 500mcg; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: Tiotropium; Assigned to Arm(s): N/A
D: Arm Label: Indacaterol 150 μg-tiotropium 18 μg-placebo; Type: EXPERIMENTAL; Interventions: Drug: Indacaterol 150 μg, Drug: Tiotropium 18 μg, Drug: Placebo | Arm Label: Tiotropium 18 μg-placebo-indacaterol 150 μg; Type: EXPERIMENTAL; Interventions: Drug: Indacaterol 150 μg, Drug: Tiotropium 18 μg, Drug: Placebo | Arm Label: Placebo-indacaterol 150 μg-tiotropium 18 μg; Type: EXPERIMENTAL; Interventions: Drug: Indacaterol 150 μg, Drug: Tiotropium 18 μg, Drug: Placebo | Intervention Type: DRUG; Name: Indacaterol 150 μg; Assigned to Arm(s): Indacaterol 150 μg-tiotropium 18 μg-placebo, Placebo-indacaterol 150 μg-tiotropium 18 μg, Tiotropium 18 μg-placebo-indacaterol 150 μg | Intervention Type: DRUG; Name: Tiotropium 18 μg; Assigned to Arm(s): Indacaterol 150 μg-tiotropium 18 μg-placebo, Placebo-indacaterol 150 μg-tiotropium 18 μg, Tiotropium 18 μg-placebo-indacaterol 150 μg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Indacaterol 150 μg-tiotropium 18 μg-placebo, Placebo-indacaterol 150 μg-tiotropium 18 μg, Tiotropium 18 μg-placebo-indacaterol 150 μg

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Dose Ranging Study to Determine the Effect of Mepolizumab on Exacerbation Rates in Subjects With Severe Uncontrolled Refractory Asthma
Brief Summary: The purpose of this study is to show whether mepolizumab given every 4 weeks intravenously (i.v.) can reduce the frequency of asthma exacerbations in subjects with severe asthma despite receiving high doses of standard asthma medications. The study will look at different doses of mepolizumab in comparison to a placebo.


Options:
A: Arm Label: OAT + Omalizumab; Type: EXPERIMENTAL; Interventions: Drug: Omalizumab, Other: Optimized asthma therapy | Arm Label: Optimized Asthma Treatment (OAT); Type: ACTIVE_COMPARATOR; Interventions: Other: Optimized asthma therapy | Intervention Type: DRUG; Name: Omalizumab; Assigned to Arm(s): OAT + Omalizumab | Intervention Type: OTHER; Name: Optimized asthma therapy; Assigned to Arm(s): OAT + Omalizumab, Optimized Asthma Treatment (OAT)
B: Arm Label: Mepolizumab 750mg; Type: ACTIVE_COMPARATOR; Interventions: Biological: Mepolizumab 750 | Arm Label: Mepolizumab 250mg; Type: ACTIVE_COMPARATOR; Interventions: Biological: Mepolizumab 250 | Arm Label: Mepolizumab 75mg; Type: ACTIVE_COMPARATOR; Interventions: Biological: Mepolizumab 75 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo saline | Intervention Type: BIOLOGICAL; Name: Mepolizumab 750; Assigned to Arm(s): Mepolizumab 750mg | Intervention Type: BIOLOGICAL; Name: Mepolizumab 250; Assigned to Arm(s): Mepolizumab 250mg | Intervention Type: BIOLOGICAL; Name: Mepolizumab 75; Assigned to Arm(s): Mepolizumab 75mg | Intervention Type: DRUG; Name: Placebo saline; Assigned to Arm(s): Placebo
C: Arm Label: 1; Type: OTHER; Interventions: Biological: IMA-638 is a biologic | Intervention Type: BIOLOGICAL; Name: IMA-638 is a biologic; Assigned to Arm(s): 1
D: Arm Label: Mepolizumab SC; Type: EXPERIMENTAL; Interventions: Biological: Mepolizumab, Drug: SOC | Arm Label: Placebo SC; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: SOC | Intervention Type: BIOLOGICAL; Name: Mepolizumab; Assigned to Arm(s): Mepolizumab SC | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo SC | Intervention Type: DRUG; Name: SOC; Assigned to Arm(s): Mepolizumab SC, Placebo SC

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Dose Ranging Study to Determine the Effect of Mepolizumab on Exacerbation Rates in Subjects With Severe Uncontrolled Refractory Asthma
Brief Summary: The purpose of this study is to show whether mepolizumab given every 4 weeks intravenously (i.v.) can reduce the frequency of asthma exacerbations in subjects with severe asthma despite receiving high doses of standard asthma medications. The study will look at different doses of mepolizumab in comparison to a placebo.


Options:
A: Arm Label: OAT + Omalizumab; Type: EXPERIMENTAL; Interventions: Drug: Omalizumab, Other: Optimized asthma therapy | Arm Label: Optimized Asthma Treatment (OAT); Type: ACTIVE_COMPARATOR; Interventions: Other: Optimized asthma therapy | Intervention Type: DRUG; Name: Omalizumab; Assigned to Arm(s): OAT + Omalizumab | Intervention Type: OTHER; Name: Optimized asthma therapy; Assigned to Arm(s): OAT + Omalizumab, Optimized Asthma Treatment (OAT)
B: Arm Label: Mepolizumab 750mg; Type: ACTIVE_COMPARATOR; Interventions: Biological: Mepolizumab 750 | Arm Label: Mepolizumab 250mg; Type: ACTIVE_COMPARATOR; Interventions: Biological: Mepolizumab 250 | Arm Label: Mepolizumab 75mg; Type: ACTIVE_COMPARATOR; Interventions: Biological: Mepolizumab 75 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo saline | Intervention Type: BIOLOGICAL; Name: Mepolizumab 750; Assigned to Arm(s): Mepolizumab 750mg | Intervention Type: BIOLOGICAL; Name: Mepolizumab 250; Assigned to Arm(s): Mepolizumab 250mg | Intervention Type: BIOLOGICAL; Name: Mepolizumab 75; Assigned to Arm(s): Mepolizumab 75mg | Intervention Type: DRUG; Name: Placebo saline; Assigned to Arm(s): Placebo
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Active; Type: ACTIVE_COMPARATOR; Interventions: Drug: GSK679586 | Intervention Type: DRUG; Name: GSK679586; Assigned to Arm(s): Active | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Omalizumab; Type: EXPERIMENTAL; Interventions: Drug: Omalizumab, Drug: Fluticasone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Fluticasone | Intervention Type: DRUG; Name: Omalizumab; Assigned to Arm(s): Omalizumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Fluticasone; Assigned to Arm(s): Omalizumab, Placebo

Answer: B